Canada faces mounting pressure to curb escalating immunoglobulin therapy consumption as healthcare stakeholders grapple with supply chain constraints and financial sustainability. The surge in plasma-derived immunoglobulin treatments reflects growing clinical demand, yet raises critical questions about long-term viability of current distribution models. Medical professionals, patients, and government agencies are collaborating on evidence-based protocols to optimize resource allocation while maintaining therapeutic access for those with genuine immunodeficiency conditions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.